Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic

Immune checkpoint inhibitors (ICPIs) have revolutionized the management and prognosis of fit patients with advanced non-small cell lung cancer (NSCLC). Recently, the publication of 5-year survival rates has cemented the role of ICPIs in NSCLC. An ongoing challenge is to determine the optimal treatme...

Full description

Bibliographic Details
Main Authors: Alex Friedlaender, Chul Kim, Alfredo Addeo
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Oncology
Subjects:
NSCLC
COVID19
immune checkpoint inhibitors
duration
first line
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00862/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00862/full

Similar Items